Moderna Inc
NASDAQ:MRNA
Moderna Inc
NASDAQ:MRNA
Price:
132.9 USD
0.17%
Market Closed
Updated:
May 20, 2024
Moderna Inc
Additional Paid In Capital
|
Moderna Inc
Additional Paid In Capital Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Moderna Inc
NASDAQ:MRNA
|
Additional Paid In Capital
$487m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$20.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$6.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$11.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
See Also
What is Moderna Inc's Additional Paid In Capital?
Additional Paid In Capital
487m
USD
487m
USD
Based on the financial report for Mar 31, 2024, Moderna Inc's Additional Paid In Capital amounts to 487m USD.
What is Moderna Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
-28%
-28%
Over the last year, the Additional Paid In Capital growth was -33%. The average annual Additional Paid In Capital growth rates for Moderna Inc have been -54% over the past three years , -28% over the past five years .
You don't have any saved screeners yet
